India, Sept. 1 -- bioAffinity Technologies (BIAF) shares surged more than 40% on Tuesday morning after the company said it is advancing the potential use of its noninvasive CyPath Lung test for surveillance of lung cancer survivors.
The stock is currently trading at $6.40, up $1.84 or 40.35%, on the Nasdaq. It opened at $7.73 after closing the previous session at $4.56. The stock has traded between $4.56 and $202.50 over the past 52 weeks. Volume stands at 35,987,906 shares, compared with an average volume of 221,257 shares.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....